Morningstar ID: 0P0001SWM3
Exchange: NASDAQ-GS
Sector: Healthcare
Industry: Diagnostics & Research
Stock Style: Small Growth
description: GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
(Generated: 2025-06-23 23:57:36)
| Income Statement As of Originally Reported | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 55550000 | 93110000 | 125600000 | 130710000 | |||||
| Revenue Growth % | - | - | - | - | 0.00 | - | - | - | 67.61 | 34.90 | 30.47 |
| Gross Profit | -116450000 | -95610000 | -78020000 | -76040000 | |||||||
| Gross Profit Margin % | - | - | - | - | - | - | - | -209.63 | -102.69 | -62.12 | -58.18 |
| Operating Income | -287500000 | -255660000 | -742460000 | -796920000 | -768220000 | -694410000 | |||||
| Operating Margin % | - | - | - | - | - | - | - | -1336.56 | -855.93 | -611.67 | -531.25 |
| EBIT | -287780000 | -257480000 | -5443130000 | -1515590000 | -2189090000 | -2115910000 | |||||
| EBIT Margin % | - | - | - | - | - | - | - | -9798.61 | -1627.83 | -1742.98 | -1618.77 |
| EBITDA | -273700000 | -247170000 | -5288370000 | -1356890000 | -2031040000 | -1958570000 | |||||
| EBITDA Margin % | - | - | - | - | - | - | - | -9520.01 | -1457.38 | -1617.13 | -1498.39 |
| Net Income | -275720000 | -244860000 | -5399100000 | -1283650000 | -2027010000 | -1914300000 | |||||
| Net Profit Margin % | - | - | - | - | - | - | - | -9719.35 | -1378.71 | -1613.92 | -1464.53 |
| Basic EPS | - | - | - | -8.88 | -7.89 | - | - | -173.87 | -41.34 | -63.54 | -60.99 |
| Diluted EPS | - | - | - | -8.88 | -7.89 | - | - | -173.87 | -41.34 | -63.54 | -60.99 |
| Normalized EPS | - | - | - | - | - | - | - | - | - | - | -14.37 |
| Dividend Per Share | - | - | - | - | - | - | - | - | - | - | - |
| Balance Sheet As of Originally Reported | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Last Quarter |
| Total Assets | 686850000 | 635520000 | 4937990000 | 3913810000 | 2983310000 | 2847610000 | |||||
| Total Liabilities | 1689700000 | 1848050000 | 291830000 | 267630000 | 479900000 | 433940000 | |||||
| Total Debt | 800000 | 41240000 | 96010000 | 84410000 | 68140000 | 64320000 | |||||
| Total Equity | -1002850000 | -1212530000 | 4646160000 | 3646190000 | 2503410000 | 2413670000 | |||||
| Cash And Cash Equivalents | 95090000 | 143190000 | 241600000 | 97290000 | 214230000 | 133900000 | |||||
| Working Capital | 575070000 | 512580000 | 160690000 | -7550000 | 742940000 | 652680000 | |||||
| Shares Outstanding Capital | 33600000 | 33600000 | |||||||||
| Book Value per Share | - | - | - | - | - | - | - | - | - | 73.86 | 68.38 |
| Debt to Equity | - | - | - | - | - | - | - | 0.02 | 0.02 | 0.03 | 0.03 |
| Cash Flow As of Originally Reported | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
| Cash From Operating Activities | -209260000 | -245790000 | -561310000 | -595800000 | -577160000 | -464880000 | |||||
| Cash From Investing Activities | -93390000 | 133040000 | -22860000 | -12890000 | -551010000 | -533850000 | |||||
| Cash From Financing Activities | 300620000 | 160330000 | 604820000 | 463770000 | 1244300000 | 932300000 | |||||
| Capital Expenditure | 15990000 | 3330000 | 22860000 | 12890000 | 5210000 | 2720000 | |||||
| Free Cash Flow | -264920000 | -209840000 | -569710000 | -616410000 | -558090000 | -454660000 | |||||
| Change in Cash | -2030000 | 47570000 | 20650000 | -144920000 | 116130000 | -66430000 |
| Unnamed: 0 | 2015-12 | 2016-12 | 2017-12 | 2018-12 | 2019-12 | 2020-12 | 2021-12 | 2022-12 | 2023-12 | 2024-12 | Latest Qtr |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue % | |||||||||||
| Year Over Year | - | - | - | - | 0.00 | - | - | - | 67.61 | 34.90 | 19.15 |
| 3-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| 5-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| 10-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income % | |||||||||||
| Year Over Year | - | - | - | - | - | - | - | - | - | - | - |
| 3-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| 5-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| 10-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| Net Income % | |||||||||||
| Year Over Year | - | - | - | - | - | - | - | - | - | - | - |
| 3-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| 5-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| 10-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| EPS % | |||||||||||
| Year Over Year | - | - | - | - | - | - | - | - | - | - | - |
| 3-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| 5-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| 10-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| Cash Flow Ratios | Unnamed: 1 | Unnamed: 2 | Unnamed: 3 | 2018-12 | 2019-12 | Unnamed: 6 | Unnamed: 7 | 2022-12 | 2023-12 | 2024-12 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow Growth % YOY | - | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow Growth % YOY | - | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow/Sales % | - | - | - | - | - | - | - | -1051.61 | -653.76 | -463.68 | -357.74 |
| Free Cash Flow/Net Income | - | - | - | 0.82 | 1.02 | - | - | 0.11 | 0.47 | 0.29 | 0.24 |
| Free Cash Flow/Share | - | - | - | - | - | - | - | - | - | -18.71 | -18.26 |
| Liquidity/Financial Health | 2015-12 | 2016-12 | 2017-12 | 2018-12 | 2019-12 | 2020-12 | 2021-12 | 2022-12 | 2023-12 | 2024-12 | Latest Qtr |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | - | - | - | 8.75 | 12.41 | - | - | 2.19 | 0.95 | 10.66 | 9.71 |
| Quick Ratio | - | - | - | 8.67 | 12.13 | - | - | 1.94 | 0.74 | 10.25 | 9.26 |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - | - |
| Financial Leverage | - | - | - | - | - | - | - | 1.06 | 1.07 | 1.19 | 1.18 |
| Debt/Equity | - | - | - | - | - | - | - | 0.02 | 0.02 | 0.02 | 0.02 |
| Book Value/Share | - | - | - | - | - | - | - | - | - | 76.35 | 70.92 |
| Cap Ex as a % of Sales | - | - | 41.15 | 13.84 | 4.15 | - | - | - | - | - | 2.08 |
| Fiscal | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Current | 5-Yr |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Asset % | - | - | - | -40.14 | -37.03 | - | - | -109.34 | -29.0 | -58.78 | -50.41 | -54.86 |
| Return on Equity % | - | - | - | - | - | - | - | -116.21 | -30.96 | -65.92 | -59.78 | -42.62 |
| Return on Invested Capital % | - | - | - | - | - | - | - | -113.89 | -30.46 | -65.12 | -59.35 | -41.89 |
| Days Sales Outstanding | - | - | - | - | - | - | - | 100.83 | 63.13 | 54.02 | 47.86 | 43.6 |
| Days Inventory | - | - | - | - | - | - | - | 41.92 | 40.08 | 36.14 | 35.57 | 23.63 |
| Payables Period | - | - | - | - | - | - | - | 32.23 | 32.91 | 21.23 | 12.89 | 17.28 |
| Cash Conversion Cycle | - | - | - | - | - | - | - | 110.52 | 70.3 | 68.93 | 70.54 | 49.95 |
| Recieveables Turnover | - | - | - | - | - | - | - | 3.62 | 5.78 | 6.76 | 7.63 | 3.23 |
| Inventory Turnover | - | - | - | - | - | - | - | 8.71 | 9.11 | 10.1 | 10.26 | 5.58 |
| Fixed Assets Turnover | - | - | - | - | - | - | - | 0.28 | 0.51 | 0.82 | 0.91 | 0.32 |
| Asset Turnover | - | - | - | - | - | - | - | 0.01 | 0.02 | 0.04 | 0.03 | 0.01 |
